A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation

Phase 2TerminatedNCT01917006

Allergan59 enrolled

Overview

This is a safety and efficacy study of OnabotulinumtoxinA for the treatment of premature ejaculation (PE) in male participants.

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-escalation study to assess a range of doses of OnabotulinumtoxinA for the treatment of male participants with PE. Participants will attend a minimum of 6 or 7 clinic visits and also have 1 or 2 telephone visits. Partners will need to attend a clinic visit during the screening period to provide informed consent and to receive training on measurement and recording of the intravaginal ejaculatory latency time (IELT). Participants will be enrolled in cohorts. Within the first 5 cohorts, 8 participants are to receive OnabotulinumtoxinA and 2 participants to receive placebo. For cohort 6, 12 participants will receive OnabotulinumtoxinA and 12 participants will receive placebo. Participants will receive a single treatment of study medication delivered bilaterally to the bulbospongiosus muscle. The initial OnabotulinumtoxinA total dose in this dose escalation study will be 5 U and the maximum OnabotulinumtoxinA total dose will be 100 U. Upon request and if eligible, participants in cohort 6, will have the option to receive a second injection of OnabotulinumtoxinA (Open-label).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Premature Ejaculation

Interventions

OnabotulinumtoxinADRUG

OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.

Normal SalineDRUG

Placebo (normal saline) injected into specified muscle per protocol on Day 1.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of premature ejaculation * Stable monogamous sexual relationship with female partner for at least 6 months, and intends to continue with the same partner for the duration of the study * Participant has ability to follow study instructions and complete study assessment tools Exclusion Criteria: * Premature ejaculation caused by medical or surgical issues, or is related to stress or other issues (eg, relationship problems) * Pain with ejaculation * Planned use of topical penile treatments (eg, anesthetics, herbal treatments) or penile injections during the study * Prior genital, prostatic or lower urinary tract surgery (other than vasectomy or circumcision) * Previous or current usage of botulinum toxin therapy of any serotype for any urological condition * Use of botulinum toxin therapy of any serotype for any nonurological condition (eg, cosmetic, chronic migraine) during the 12 weeks prior to screening, or planned usage during the study * Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis

Locations (10)

San Diego Sexual Medicine

San Diego, California, United States

LA Biomedical Research Institute at Harbor-UCLA Medical Center

Torrance, California, United States

Connecticut Clinical Research Center

Middlebury, Connecticut, United States

Outcomes

Primary Outcomes

Change From Baseline in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT)

IELT, the time from vaginal penetration to ejaculation, was measured by a stopwatch and was recorded in the sexual intercourse diary (SID). The Logarithm Value of the Geometric Mean of each individual participant's IELT recorded in the SID up to each time point was calculated. The mean and standard deviation (SD) of log-transformed geometric mean IELTs are then calculated for each treatment group. An Analysis of Covariance (ANCOVA) Model with treatment as the fixed effect and baseline geometric mean IELT as the covariate was used for analyses. A positive change from Baseline indicates improvement.

Time frame: Baseline (Day 1) to Week 12

Secondary Outcomes

Change From Baseline in Average IELT

IELT, the time from vaginal penetration to ejaculation, was measured by a stopwatch and was recorded in the SID. The average of each individual participant's IELT recorded in the SID up to each time point was calculated. The mean and SD of average IELTs were then calculated for each treatment group. An ANCOVA Model with treatment as the fixed effect and baseline average mean IELT as the covariate was used for analyses. A positive change from Baseline indicates improvement.

Time frame: Baseline (Day 1) to Weeks 2, 4, 6, 8, 10, and 12

Change From Baseline in Geometric Mean IELT

IELT, the time from vaginal penetration to ejaculation, was measured by a stopwatch and was recorded in the SID. The Logarithm Value of the Geometric Mean of each individual participant's IELT recorded in the SID up to each time point was calculated. The mean and SD of log-transformed geometric mean IELTs were then calculated for each treatment group. An ANCOVA Model with treatment as the fixed effect and baseline geometric mean IELT as the covariate was used for analyses. A positive change from Baseline indicates improvement.

Time frame: Baseline (Day 1) to Weeks 2, 4, 6, 8, and 10

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.